PrandiMet is a combination drug that encompasses Prandin and metformin to treat Type 2 diabetes.
Type 2 diabetic patients have a new drug to treat their disease. It’s PrandiMet (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide (Prandin, Novo Nordisk) and insulin sensitizer, metformin. The combination drug is designed to lower the blood glucose of Type 2 diabetics whose hyperglycemia cannot be controlled by meglitinide and/or metformin. To be marketed by Sciele Pharma, the drug will be available in two dosage strengths-1 mg (repaglinide)/500mg (metformin) and 2 mg (repaglinide)/500 mg (metformin)-for administration at two to three times a day with meals.
